Anti-Malarial Drug for Treatment of Covid-19 approved by ICMR
National Task Force for Covid-19
constituted by Indian Council of Medical Research (ICMR) has recommended the
use of hydroxy-chloroquine for prophylaxis of SARS-Cov-2 as a preventive for
high risk population that includes asymptomatic health care workers involved in
the care of suspected or confirmed cases of Covid-19, asymptomatic household
contacts of laboratory confirmed cases. However, Drugs Controller General of
India has said that intake of such medicine should neot give a false sense of
security. Those taking such medicine
should continue to take presribed public health measures such as frequent hand
washing, respiratory etiquettes, social distancing of one metre and use of
protective equipment where required.
The high risk contacts of a positive case placed under chemo prophylaxis should remain in home quarantine while on prophylacti therapy.
The dosage for Covid treatment is 400 mg twice a day on Day 1 followed by 400 mg once weekly for next next 7 weeks to be taken with meals. (asymptomatic healthcare workers), and 400 mg twice a day on Day 1, followed by 400 mg once weekly for next 3 weeks to be taken with meals for asymptomatic household contacts of laboratory confirmed cases.
It is not to be used in children below 15 years of age and contraindicated in persons with known case of retinopathy, known hypersensitivity to hydroxychioroquine, 4-aminoquinoline compounds.
More details in: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf